by Mouna Daldoul  , Rim Charfi  , Khouloud Ferchichi  , Mouna Ben Sassi  , Syrine Ben Hammamia  , Fatma Medhioub  , Emna Gaies  , Rym Enneifer  , Hanene Eljebari  , Anis Klouz  , Riadh Daghfous  and Sameh Trabelsi

Received: 20 August 2024;  Published: 13 December 2024;  doi: 10.21926/obm.transplant.2404228

Background: Tacrolimus is characterized by a high intra and interindividual pharmacokinetics variability. Data regarding factors that may influence its pharmacokinetics and pharmacodynamics in liver transplantation are limited. The objectives of this study were to assess tacrolimus therapeutic response, pharmacokinetics and adherence in liver transplant recipients. Methods: The study was conducted at the Clinical Pharmacology Department over a period of 12 years from January 2009 to March 2021. We included liver tr [...]

by Michael Y. Shino  , Francisco Javier Ibarrondo  , Jesse L. Clark  , Adreanne Rivera  , Marlene Florian  , Allison Ramsey  , Ariss Derhovanessian  , Rajan Saggar  , Olawale O. Amubieya  , Grant Turner  , Joanna M. Schaenman  , Pryce T. Gaynor  , Omer E. Beaird  , Ashrit Multani  , Reshma M. Biniwale  , Murray H. Kwon  , Christos J. Petropoulos  , Yolanda Lie  , Terri Wrin  , Amparo L. Figueroa  , Brett Leav  , Zelalem Endale  , Kate Anteyi  , Jacqueline M. Miller  , Abbas Ardehali  , David M. Sayah  , David Elashoff  , John A. Belperio  , Otto O. Yang  and S. Sam Weigt

Received: 16 August 2024;  Published: 20 November 2024;  doi: 10.21926/obm.transplant.2404227

Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 booster vaccines among lung transplant recipients (LTRs). This phase 1/2 open-label randomized clinical trial of higher-dose mRNA-1273 booster vaccination enrolled nineteen adult LTRs into the 50 ug (n=8) vs. 100 ug (n=11) groups before enrollment was terminated due to the availability of the bivalent mRNA-1273.222 vaccine. Local and syst [...]

by Sabrine Mekni  , Lamia Torjemane  , Malek Khayati  , Dorra Belloumi  , Rimmel Yosra Kanoun  , Insaf Ben Yaiche  , Rihab Ouerghi  , Ines Turki  , Saloua Ladeb  , Tarek Ben Othman  and Nour Ben Abdeljelil

Received: 29 June 2024;  Published: 11 November 2024;  doi: 10.21926/obm.transplant.2404226

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) remains the only curative treatment for bone marrow failure (BMF) and hematologic complications of Fanconi anemia (FA). The evolution remains affected by the toxicity, the risk of graft failure, and clonal evolution. This study aimed to identify factors affecting outcomes in FA patients after allo-HSCT. We included FA patients who underwent allo-HSCT between January 2006 and December 2021. The conditioning regimen was cyclophosphamide/fludarabine (Cy/Fl [...]

by Elga J. Vargas  , Julio C. Martinez  and Lina A. Gomez

Received: 26 April 2024;  Published: 03 October 2024;  doi: 10.21926/obm.transplant.2404225

Acne is a chronic inflammatory condition affecting the pilosebaceous units of the skin, characterized by the formation of papules, cysts, comedones, pustules, nodules, and scars. These lesions are typically located on the face and shoulders, although they can extend to the trunk, arms, and legs. In regenerative medicine, biomolecules are fundamental to tissue regeneration. The use of growth factors from autologous platelet-rich plasma emerges as a promising alternative in the treatment of acne and scars. This study [...]

by Yue Qiu  , Yinqian Kang  , Hao Liu  and Ibtesam Hilmi

Received: 12 May 2024;  Published: 30 August 2024;  doi: 10.21926/obm.transplant.2403224

Machine perfusion (MP) techniques, which simulate physiological conditions to allow for the assessment and preservation of organ viability, are currently applied in various solid organ transplantation fields. Owing to the growing demand for liver transplants and the scarcity of available donor livers, MP offers a practical solution for recovering high-risk grafts and increasing the number of potentially usable donor organs. Furthermore, testing and administering novel therapies to allografts may also become advanta [...]

by Elga Johanna Vargas  , Ana Luisa Muñoz  and Lina Andrea Gómez

Received: 21 May 2024;  Published: 13 August 2024;  doi: 10.21926/obm.transplant.2403223

Platelets were the last to be discovered of the three formed blood elements. Several scientists have been interested in them, recognizing them as cells other than leukocytes and erythrocytes. Its job in hemostasis and thrombosis is currently known. Platelets contain growth factors and secrete cytokines, which have roles in inflammation and tissue regeneration processes. This is why platelet concentrates have been widely used in regenerative medicine, an emerging field that involves biomolecules, cells, and scaffold [...]

by Sanjay Dutta  , Jeanette E. Villanueva  , Yashutosh Joshi  , Ling Gao  , Paul Jansz  and Peter S. Macdonald

Received: 02 April 2024;  Published: 05 August 2024;  doi: 10.21926/obm.transplant.2403222

Heart transplantation remains the gold standard treatment for end-stage heart failure. With an increasing population and improving medical therapy there is an increasing number of patients who would benefit from heart transplantation but are unable to receive one due to a shortage of suitable donor organs. This ongoing need, and significant limitations with traditional cold static storage (CSS), have driven the development of machine perfusion technology that have expanded the donor pool. Machine perfusion is divid [...]

by Yassamine Bentata

Received: 24 January 2024;  Published: 25 July 2024;  doi: 10.21926/obm.transplant.2403221

Completely unknown before the 90s and exceptional up to the 2000s, BK virus nephropathy (BKvN), usually known as polyomavirus-associated nephropathy, has emerged as a significant and severe viral complication in kidney transplantation (KT). More than twenty years after Gardner's discovery of BKv in 1971, Purighalla described, in 1995, the first case of BKvN. Four years later in 1999, Nickeleit et al. published a first series of five cases of BKvN and made very precious and pertinent contributions to understanding t [...]

by Van Anh Vu  , Joelle Nelson  , Helen Sweiss  , Reed Hall  , Holly Keyt  and Elisabeth Kincaide

Received: 29 January 2024;  Published: 03 July 2024;  doi: 10.21926/obm.transplant.2403220

Secondary hypogammaglobulinemia (HGG) from immunosuppression therapy in lung transplant recipients has been associated with increased mortality, morbidity and higher risk of infection. Intravenous immunoglobulin (IVIG) for the treatment of HGG post-lung transplant is not well studied with conflicting evidence regarding efficacy. This single-center, retrospective cohort study analyzed adult lung transplant recipients with HGG receiving ≥1 dose of IVIG 0.3-0.5 g/kg. Resolution of HGG (IgG > 600 mg/dL within 30 days o [...]

by Andrés R. Latorre-Rodríguez  , Devika Sindu  , Sumeet K. Mittal  and Ashwini Arjuna

Received: 23 February 2024;  Published: 21 June 2024;  doi: 10.21926/obm.transplant.2402219

Activated pepsin (pepA) in bronchoalveolar lavage (BAL) fluid may be a biomarker of gastric aspiration. We sought to i) evaluate the association of pepA in BAL fluid with acute cellular rejection (ACR) in a cohort of lung transplant recipients (LTRs), ii) assess the association between pepA and isolation of typical gastrointestinal microorganisms from BAL fluid, and iii) explore the accuracy of using pepA concentration as a biomarker of ACR. After IRB approval, we conducted a retrospective observational study analy [...]